Rabies Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests), By Technology Method (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Others), By Region & Competition, 2021-2031F
The Global Rabies Diagnostics Market is projected to increase from a valuation of USD 2.78 Billion in 2025 to USD 4.46 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.20%. This market segment includes in vitro diagnostic methodologies such as Direct Fluorescent Antibody (DFA) testing, Polymerase Chain Reaction (PCR), and Enzyme-Linked Immunosorbent Assays (ELISA), which are utilized to detect the rabies virus in specimens from both humans and animals. Market expansion is largely fueled by the rising incidence of zoonotic diseases and intensified 'One Health' efforts aimed at eradicating dog-mediated rabies. Additionally, growing rates of pet ownership and the enforcement of strict government mandates regarding animal vaccination and cross-border transport are boosting the demand for fast and precise diagnostic tools.
A major obstacle hindering market progress is the prohibitive cost of advanced diagnostic technologies combined with the insufficiency of laboratory infrastructure in developing nations, where the burden of disease is most severe. This inequality restricts the broader application of sophisticated testing protocols in resource-limited areas. As reported by the American Veterinary Medical Association in 2024, approximately 89,530 animal specimens were submitted for rabies testing within the United States during the preceding surveillance interval. While such figures underscore the essential nature of consistent surveillance, financial limitations in emerging markets persist in limiting global access to these critical diagnostic resources.
Market Driver
Strategic international initiatives designed to achieve rabies elimination by 2030 are significantly transforming the diagnostics landscape by securing funding and prioritizing surveillance in endemic zones. Global organizations are increasingly incorporating rabies control into comprehensive healthcare investment frameworks, establishing a solid foundation for sustainable market growth. Highlighting this shift, the World Health Organization noted in June 2024 that the Gavi Board approved the addition of human rabies vaccines for post-exposure prophylaxis to its investment strategy, a decision anticipated to systematically enhance access to care and drive the need for improved diagnostic tracking in eligible nations. This strategic realignment targets the significant economic impact of the disease; the U.S. Department of Agriculture estimated in August 2024 that the aggregate annual costs for rabies detection, prevention, and control in the United States alone exceed $500 million.
Simultaneously, technological progress in molecular and lateral flow diagnostic assays is widening market access by providing fast, affordable options adaptable to various testing settings. Manufacturers are vigorously creating and releasing immunoassay-based solutions that decrease dependence on sophisticated laboratory setups, thereby boosting testing rates in both veterinary and human health sectors. For example, BioStone Animal Health reported in February 2024 the commercial release of the AsurDx Rabies Antibody Test Kit, an ELISA-based product engineered for the swift identification of rabies virus antibodies in mammalian serum. These innovations are essential to satisfy the increasing requirement for effective vaccine monitoring and disease surveillance, ensuring diagnostic capacities align with global elimination targets.
Market Challenge
The substantial expense associated with sophisticated diagnostic technologies, coupled with the scarcity of laboratory infrastructure in developing countries, presents a significant barrier to the growth of the Global Rabies Diagnostics Market. Although advanced techniques like Polymerase Chain Reaction (PCR) and Direct Fluorescent Antibody (DFA) testing provide superior sensitivity, they necessitate heavy capital expenditure on machinery, reliable power supplies, and specialized personnel. These prerequisites are frequently missing in low-resource areas where the disease is most endemic, creating an economic divide that effectively blocks the adoption of dependable testing kits and compels healthcare systems to rely on clinical observation rather than purchasing diagnostic solutions.
Consequently, the market struggles to penetrate regions that theoretically possess the highest patient volumes, thereby confining revenue generation primarily to developed nations with mature surveillance networks. This failure to secure a position in high-burden countries dampens global transaction volumes and discourages manufacturers from scaling distribution networks in emerging economies. According to the World Health Organization, the global economic burden of rabies was estimated at approximately US$ 8.6 billion annually in 2024, a statistic that underscores the profound financial restrictions limiting the ability of these health systems to fund essential diagnostic procurement.
Market Trends
The market is increasingly prioritizing genomic sequencing and variant typing over simple presence-absence detection to support precise epidemiological tracking. Laboratories are shifting from traditional Direct Fluorescent Antibody (DFA) testing toward molecular characterization to identify specific viral lineages and monitor cross-species transmission pathways. This evolution allows public health authorities to distinguish between indigenous and translocated variants, which is crucial for targeted intervention strategies in non-endemic zones. According to the American Veterinary Medical Association, July 2025, in the 'Rabies surveillance in the United States during 2023' report, 35.6% of all positive rabies samples underwent virus characterization to identify specific variants, underscoring the growing reliance on advanced molecular insights for disease management.
There is a distinct trend toward widening surveillance architectures to capture wildlife reservoirs that pose a persistent threat to urban and peri-urban populations. Unlike traditional models focused on domestic animals, these expanded networks focus on monitoring distinct wildlife vectors such as bats and foxes, which serve as primary reservoirs in regions where dog-mediated rabies is controlled. This shift necessitates the integration of regional data into broader national tracking systems to detect spillover events early. For instance, according to the Canadian Animal Health Surveillance System, February 2025, in the 'Status Update for Rabies' report, confirmed cases of bat variant rabies in Ontario reached 91 in 2024, highlighting the critical need for sustained wildlife monitoring to prevent reintroduction into domestic populations.
Key Market Players
In this report, the Global Rabies Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Rabies Diagnostics Market.
Available Customizations:
Global Rabies Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
A major obstacle hindering market progress is the prohibitive cost of advanced diagnostic technologies combined with the insufficiency of laboratory infrastructure in developing nations, where the burden of disease is most severe. This inequality restricts the broader application of sophisticated testing protocols in resource-limited areas. As reported by the American Veterinary Medical Association in 2024, approximately 89,530 animal specimens were submitted for rabies testing within the United States during the preceding surveillance interval. While such figures underscore the essential nature of consistent surveillance, financial limitations in emerging markets persist in limiting global access to these critical diagnostic resources.
Market Driver
Strategic international initiatives designed to achieve rabies elimination by 2030 are significantly transforming the diagnostics landscape by securing funding and prioritizing surveillance in endemic zones. Global organizations are increasingly incorporating rabies control into comprehensive healthcare investment frameworks, establishing a solid foundation for sustainable market growth. Highlighting this shift, the World Health Organization noted in June 2024 that the Gavi Board approved the addition of human rabies vaccines for post-exposure prophylaxis to its investment strategy, a decision anticipated to systematically enhance access to care and drive the need for improved diagnostic tracking in eligible nations. This strategic realignment targets the significant economic impact of the disease; the U.S. Department of Agriculture estimated in August 2024 that the aggregate annual costs for rabies detection, prevention, and control in the United States alone exceed $500 million.
Simultaneously, technological progress in molecular and lateral flow diagnostic assays is widening market access by providing fast, affordable options adaptable to various testing settings. Manufacturers are vigorously creating and releasing immunoassay-based solutions that decrease dependence on sophisticated laboratory setups, thereby boosting testing rates in both veterinary and human health sectors. For example, BioStone Animal Health reported in February 2024 the commercial release of the AsurDx Rabies Antibody Test Kit, an ELISA-based product engineered for the swift identification of rabies virus antibodies in mammalian serum. These innovations are essential to satisfy the increasing requirement for effective vaccine monitoring and disease surveillance, ensuring diagnostic capacities align with global elimination targets.
Market Challenge
The substantial expense associated with sophisticated diagnostic technologies, coupled with the scarcity of laboratory infrastructure in developing countries, presents a significant barrier to the growth of the Global Rabies Diagnostics Market. Although advanced techniques like Polymerase Chain Reaction (PCR) and Direct Fluorescent Antibody (DFA) testing provide superior sensitivity, they necessitate heavy capital expenditure on machinery, reliable power supplies, and specialized personnel. These prerequisites are frequently missing in low-resource areas where the disease is most endemic, creating an economic divide that effectively blocks the adoption of dependable testing kits and compels healthcare systems to rely on clinical observation rather than purchasing diagnostic solutions.
Consequently, the market struggles to penetrate regions that theoretically possess the highest patient volumes, thereby confining revenue generation primarily to developed nations with mature surveillance networks. This failure to secure a position in high-burden countries dampens global transaction volumes and discourages manufacturers from scaling distribution networks in emerging economies. According to the World Health Organization, the global economic burden of rabies was estimated at approximately US$ 8.6 billion annually in 2024, a statistic that underscores the profound financial restrictions limiting the ability of these health systems to fund essential diagnostic procurement.
Market Trends
The market is increasingly prioritizing genomic sequencing and variant typing over simple presence-absence detection to support precise epidemiological tracking. Laboratories are shifting from traditional Direct Fluorescent Antibody (DFA) testing toward molecular characterization to identify specific viral lineages and monitor cross-species transmission pathways. This evolution allows public health authorities to distinguish between indigenous and translocated variants, which is crucial for targeted intervention strategies in non-endemic zones. According to the American Veterinary Medical Association, July 2025, in the 'Rabies surveillance in the United States during 2023' report, 35.6% of all positive rabies samples underwent virus characterization to identify specific variants, underscoring the growing reliance on advanced molecular insights for disease management.
There is a distinct trend toward widening surveillance architectures to capture wildlife reservoirs that pose a persistent threat to urban and peri-urban populations. Unlike traditional models focused on domestic animals, these expanded networks focus on monitoring distinct wildlife vectors such as bats and foxes, which serve as primary reservoirs in regions where dog-mediated rabies is controlled. This shift necessitates the integration of regional data into broader national tracking systems to detect spillover events early. For instance, according to the Canadian Animal Health Surveillance System, February 2025, in the 'Status Update for Rabies' report, confirmed cases of bat variant rabies in Ontario reached 91 in 2024, highlighting the critical need for sustained wildlife monitoring to prevent reintroduction into domestic populations.
Key Market Players
- Bio-Rad Laboratories, Inc
- Merck KGaA
- Aviva Systems Biology Corporation.
- Creative Diagnostics
- Demeditec Diagnostics GmbH.
- Abbexa Ltd.
- Norgen Biotek Corp.
- BioNote, Inc.
- Express Biotech International Inc.
In this report, the Global Rabies Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Rabies Diagnostics Market, By Diagnostic Method
- Fluorescent Antibody Test (FAT)
- Immunohistochemical Test
- Amplification Methods
- Histologic Examination
- Serology Tests
- Rabies Diagnostics Market, By Technology Method
- ELISA/Immunohistochemistry
- Chromatography Techniques
- PCR
- Others
- Rabies Diagnostics Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Rabies Diagnostics Market.
Available Customizations:
Global Rabies Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RABIES DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests)
5.2.2. By Technology Method (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA RABIES DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnostic Method
6.2.2. By Technology Method
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Rabies Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnostic Method
6.3.1.2.2. By Technology Method
6.3.2. Canada Rabies Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnostic Method
6.3.2.2.2. By Technology Method
6.3.3. Mexico Rabies Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnostic Method
6.3.3.2.2. By Technology Method
7. EUROPE RABIES DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnostic Method
7.2.2. By Technology Method
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Rabies Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnostic Method
7.3.1.2.2. By Technology Method
7.3.2. France Rabies Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnostic Method
7.3.2.2.2. By Technology Method
7.3.3. United Kingdom Rabies Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnostic Method
7.3.3.2.2. By Technology Method
7.3.4. Italy Rabies Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnostic Method
7.3.4.2.2. By Technology Method
7.3.5. Spain Rabies Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnostic Method
7.3.5.2.2. By Technology Method
8. ASIA PACIFIC RABIES DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnostic Method
8.2.2. By Technology Method
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Rabies Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnostic Method
8.3.1.2.2. By Technology Method
8.3.2. India Rabies Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnostic Method
8.3.2.2.2. By Technology Method
8.3.3. Japan Rabies Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnostic Method
8.3.3.2.2. By Technology Method
8.3.4. South Korea Rabies Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Diagnostic Method
8.3.4.2.2. By Technology Method
8.3.5. Australia Rabies Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Diagnostic Method
8.3.5.2.2. By Technology Method
9. MIDDLE EAST & AFRICA RABIES DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnostic Method
9.2.2. By Technology Method
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Rabies Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnostic Method
9.3.1.2.2. By Technology Method
9.3.2. UAE Rabies Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnostic Method
9.3.2.2.2. By Technology Method
9.3.3. South Africa Rabies Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnostic Method
9.3.3.2.2. By Technology Method
10. SOUTH AMERICA RABIES DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnostic Method
10.2.2. By Technology Method
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Rabies Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnostic Method
10.3.1.2.2. By Technology Method
10.3.2. Colombia Rabies Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnostic Method
10.3.2.2.2. By Technology Method
10.3.3. Argentina Rabies Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnostic Method
10.3.3.2.2. By Technology Method
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL RABIES DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Bio-Rad Laboratories, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Aviva Systems Biology Corporation.
15.4. Creative Diagnostics
15.5. Demeditec Diagnostics GmbH.
15.6. Abbexa Ltd.
15.7. Norgen Biotek Corp.
15.8. BioNote, Inc.
15.9. Express Biotech International Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RABIES DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests)
5.2.2. By Technology Method (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA RABIES DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnostic Method
6.2.2. By Technology Method
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Rabies Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnostic Method
6.3.1.2.2. By Technology Method
6.3.2. Canada Rabies Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnostic Method
6.3.2.2.2. By Technology Method
6.3.3. Mexico Rabies Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnostic Method
6.3.3.2.2. By Technology Method
7. EUROPE RABIES DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnostic Method
7.2.2. By Technology Method
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Rabies Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnostic Method
7.3.1.2.2. By Technology Method
7.3.2. France Rabies Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnostic Method
7.3.2.2.2. By Technology Method
7.3.3. United Kingdom Rabies Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnostic Method
7.3.3.2.2. By Technology Method
7.3.4. Italy Rabies Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnostic Method
7.3.4.2.2. By Technology Method
7.3.5. Spain Rabies Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnostic Method
7.3.5.2.2. By Technology Method
8. ASIA PACIFIC RABIES DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnostic Method
8.2.2. By Technology Method
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Rabies Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnostic Method
8.3.1.2.2. By Technology Method
8.3.2. India Rabies Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnostic Method
8.3.2.2.2. By Technology Method
8.3.3. Japan Rabies Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnostic Method
8.3.3.2.2. By Technology Method
8.3.4. South Korea Rabies Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Diagnostic Method
8.3.4.2.2. By Technology Method
8.3.5. Australia Rabies Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Diagnostic Method
8.3.5.2.2. By Technology Method
9. MIDDLE EAST & AFRICA RABIES DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnostic Method
9.2.2. By Technology Method
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Rabies Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnostic Method
9.3.1.2.2. By Technology Method
9.3.2. UAE Rabies Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnostic Method
9.3.2.2.2. By Technology Method
9.3.3. South Africa Rabies Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnostic Method
9.3.3.2.2. By Technology Method
10. SOUTH AMERICA RABIES DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnostic Method
10.2.2. By Technology Method
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Rabies Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnostic Method
10.3.1.2.2. By Technology Method
10.3.2. Colombia Rabies Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnostic Method
10.3.2.2.2. By Technology Method
10.3.3. Argentina Rabies Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnostic Method
10.3.3.2.2. By Technology Method
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL RABIES DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Bio-Rad Laboratories, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Aviva Systems Biology Corporation.
15.4. Creative Diagnostics
15.5. Demeditec Diagnostics GmbH.
15.6. Abbexa Ltd.
15.7. Norgen Biotek Corp.
15.8. BioNote, Inc.
15.9. Express Biotech International Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
